The role of stem-cell transplantation in the treatment of marginal zone lymphoma.
Best Pract Res Clin Haematol
; 30(1-2): 166-171, 2017.
Article
en En
| MEDLINE
| ID: mdl-28288712
ABSTRACT
High-dose chemotherapy and autologous stem-cell transplantation (ASCT) is standard therapy in relapsed/refractory aggressive lymphoma. The optimal therapy of relapsed/refractory disseminated marginal-zone lymphoma (MZL) has not been defined. Limited data on ASCT in this setting suggests outcomes are similar to what is expected in follicular lymphoma. International guidelines suggest that ASCT should be considered in follicular lymphoma in second or subsequent remission, in particular in high-risk disease, or following disease transformation. These guidelines can be extrapolated to MZL. ASCT is not considered curative but a subset of patients achieve very long remissions. The major concern is the occurrence of secondary malignancies possibly related to total-body irradiation. Allogeneic SCT is usually considered after failure of ASCT, but can also be considered upfront in younger patients seeking curative approach. The introduction of novel/targeted therapies may change the role and timing SCT may have in the treatment algorithm of indolent lymphomas.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Métodos Terapéuticos y Terapias MTCI:
Terapias_manuales
/
Masoterapia
Asunto principal:
Algoritmos
/
Linfoma de Células B de la Zona Marginal
/
Trasplante de Células Madre
Tipo de estudio:
Guideline
Idioma:
En
Revista:
Best Pract Res Clin Haematol
Año:
2017
Tipo del documento:
Article